Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis

Affiliations

¹ Dept of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
² Division of Asthma, Allergy and Lung Biology, King's College London, London, UK.
³ Dept of Clinical and Experimental Medicine, Section of Respiratory Disease, University of Catania, Catania, Italy.
⁴ Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
⁵ National Heart and Lung Institute, Imperial College London, London, UK.
⁶ Dept of Respiratory Medicine, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
⁷ Dept of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands m.wijsenbeek-lourens@erasmusmc.nl.

Observational Study

Mirjam J G van Manen et al. Eur Respir J. 2017.

. 2017 Oct 19;50(4):1701157.

doi: 10.1183/13993003.01157-2017. Print 2017 Oct.

¹ Dept of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
² Division of Asthma, Allergy and Lung Biology, King's College London, London, UK.
³ Dept of Clinical and Experimental Medicine, Section of Respiratory Disease, University of Catania, Catania, Italy.
⁴ Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
⁵ National Heart and Lung Institute, Imperial College London, London, UK.
⁶ Dept of Respiratory Medicine, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
⁷ Dept of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands m.wijsenbeek-lourens@erasmusmc.nl.

Abstract

In patients with IPF, pirfenidone reduces objective 24-h cough counts and improves subjective measures of cough http://ow.ly/iiGu30f7Pea

1. Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA). The voice of the patient; a series of reports from the U.S. Food and Drug Administration's (FDA's) Patient-Focused Drug Development Initiative. Idiopathic Pulmonary Fibrosis. March2015. www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM44... Date last updated: March 2015. Date last accessed: January 2017.
1. Key AL, Holt K, Hamilton A, et al.Objective cough frequency in idiopathic pulmonary fibrosis. Cough 2010; 6: 4. - PMC - PubMed
1. Ryerson CJ, Abbritti M, Ley B, et al.Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011; 16: 969–975. - PubMed
1. Hope-Gill BDM, Hilldrup S, Davies C, et al.A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 995–1002. - PubMed
1. Azuma A, Taguchi Y, Ogura T, et al.Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011; 12: 143. - PMC - PubMed